Industries > Pharma > Clinical Trial Supplies Market Report 2024-2034
Back to Pharma Reports
Clinical Trial Supplies Market Report 2024-2034

Clinical Trial Supplies Market Report 2024-2034

Forecasts by Location (Offshore Clinical Site, Domestic Clinical Site), by Type (Small Molecule Products, Biologic Products, Medical Devices), by Services (Manufacturing (Assays and Test Kits, Investigational Medicinal Products (IMPs) and INDs (Investigational New Drugs), Placebos, Other), Packaging and Labelling, Logistics & Distribution (Cold Chain Distribution, Non-cold Chain Distribution), Storage & Retention, Comparator Sourcing, Other), by Therapeutic Areas (Oncology, CNS and Mental Disorders, Cardiovascular Disease (CVD), Infectious Disease, Immunology Disease, Blood Disorders, Metabolic Disorders, Digestive Disorders, Other)), by Phase (Phase I, Phase II, Phase III, Phase IV), by End-users (Pharmaceutical and Biotechnology Companies, Contract Research Organisations, Medical Device Companies, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

PUBLISHED: 14 March 2024
PAGES: 373
PRODUCT CODE: PHA1321
SUBMARKET: Contract Services

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA1321 Categories: , Tag:

The Clinical Trial Supplies Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Opportunities in Emerging Markets Projected to Boost Industry Growth

Clinical trials are increasingly moving to developing economies like China, India, and Japan in the Asia Pacific region, with significant growth in patient recruitment in countries such as China, South Korea, and India due to lower costs compared to developed nations. Early phase clinical trials in developing nations are notably cheaper, making them an attractive option for pharmaceutical companies. For instance, in November 2023, AstraZeneca forged a partnership with a Chinese biotechnology company to secure a position in the competitive KRAS G12D field, exchanging $24 million upfront. The agreement grants AstraZeneca a worldwide license to UA022, a small molecule inhibitor targeting the historically challenging oncogene, which was undergoing preclinical development at Usynova. The Chinese biotech, in collaboration with partners such as WuXi AppTec, spearheaded the discovery and advancement of the molecule, ultimately determining that AstraZeneca’s offer, which includes potential milestone payments totalling up to $395 million, was highly compelling and thus opted to accept it. Also, in November 2023, Novartis entered into an agreement with Chong Kun Dang Pharmaceutical, a biotechnology company based in Korea, for an early-stage HDAC6 Inhibitor. As per the contract terms, Novartis will provide an initial payment of $80 million and commit to additional development and regulatory milestone payments amounting to nearly $1.23 billion. These trends reflect a strategic shift towards countries offering lower operational expenses for clinical trials.

Challenges Posed by Lack of Comparator Sourcing

The clinical trial supplies market faces significant hurdles due to restrictions imposed by pharmaceutical manufacturers on procuring their products as comparators for clinical trials. These limitations typically encompass quantity constraints, prolonged approval procedures, and additional disclosure requirements, posing challenges for researchers and clinical trial supply chain management. Biologics, in particular, accentuate these difficulties as the lack of internal protocols and procedures from manufacturers exacerbates the situation. For instance, Sharp Clinical Services specializes in offering solutions for clinical trial supply chains, with a focus on comparator sourcing and supply. They cater to pharmaceutical companies conducting clinical trials, aiming to streamline the procurement process. Such firms play a pivotal role in addressing the challenges linked to comparator sourcing, thereby enhancing the efficiency of the clinical trial supply chain. Pharmaceutical manufacturers often impose strict quantity limits on procuring their products for use as comparators in clinical trials. Additionally, obtaining approval for these products can be time-consuming.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the clinical trial supplies market evolving?
  • What is driving and restraining the clinical trial supplies market?
  • How will each clinical trial supplies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each clinical trial supplies submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading clinical trial supplies markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the clinical trial supplies projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of clinical trial supplies projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the clinical trial supplies market?
  • Where is the clinical trial supplies market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the clinical trial supplies market today, and over the next 10 years:

  • Our 373-page report provides 155 tables and 243 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them – NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the clinical trial supplies market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising clinical trial supplies prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Location

  • Offshore Clinical Site
  • Domestic Clinical Site

Type

  • Small Molecule Products
  • Biologic Products
  • Medical Devices

Services

  • Manufacturing
    – Assays and Test Kits
    – IMPs and INDs
    – Placebos
    – Others
  • Packaging and Labelling
  • Logistics & Distribution
    – Cold Chain Distribution
    – Non-cold Chain Distribution
  • Storage & Retention
  • Comparator Sourcing
  • Other CTS Services

Therapeutic Areas

  • Oncology
  • CNS and Mental Disorders
  • Cardiovascular Disease (CVD)
  • Infectious Disease
  • Immunology Disease
  • Blood Disorders
  • Metabolic Disorders
  • Digestive Disorders
  • Other Therapeutic Areas

Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

End-users

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Medical Device Companies
  • Other End-users

CTA

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

Clinical Trial Supplies Market Report 2024-2034
Need industry data? Please contact us today.

The report also includes profiles and for some of the leading companies in the Clinical Trial Supplies Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

  • Biocair
  • Bionical Limited
  • Catalent Inc.
  • Eurofins Scientific SE
  • ICON plc
  • IQVIA Holdings Inc.
  • KLIFO
  • Lonza Group AG
  • Marken
  • Parexel International
  • PCI Pharma Services
  • Sharp Services, LLC
  • Thermo Fisher Scientific Inc.
  • Walden Group SAS

Overall world revenue for Clinical Trial Supplies Market, 2024 to 2034 in terms of value the market will surpass US$4,100.0 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Clinical Trial Supplies Market, 2024 to 2034 report help you?

In summary, our 370+ page report provides you with the following knowledge:

  • Revenue forecasts to 2034 for Clinical Trial Supplies Market, 2024 to 2034, with forecasts for location, type, services, therapeutic areas, phase, and end-users, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2034 for five regional and 22 key national markets – See forecasts for the Clinical Trial Supplies Market, 2024 to 2034 market in North America, Europe, Asia Pacific, Latin America, and MEA. Also includes forecast for the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market – including company profiles for 14 of the major companies involved in the Clinical Trial Supplies Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Clinical Trial Supplies Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Clinical Trial Supplies Market Report 2024-2034: Forecasts by Location (Offshore Clinical Site, Domestic Clinical Site), by Type (Small Molecule Products, Biologic Products, Medical Devices), by Services (Manufacturing (Assays and Test Kits, Investigational Medicinal Products (IMPs) and INDs (Investigational New Drugs), Placebos, Other), Packaging and Labelling, Logistics & Distribution (Cold Chain Distribution, Non-cold Chain Distribution), Storage & Retention, Comparator Sourcing, Other), by Therapeutic Areas (Oncology, CNS and Mental Disorders, Cardiovascular Disease (CVD), Infectious Disease, Immunology Disease, Blood Disorders, Metabolic Disorders, Digestive Disorders, Other)), by Phase (Phase I, Phase II, Phase III, Phase IV), by End-users (Pharmaceutical and Biotechnology Companies, Contract Research Organisations, Medical Device Companies, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Clinical Trial Supplies Market Report 2024-2034

    Related reports

    Download sample pages

    Complete the form below to download your free sample pages for Clinical Trial Supplies Market Report 2024-2034

      Connect with us

      Visiongain Pharma

      Visiongain Pharma

      Visiongain Pharma

      Latest Pharma news

      Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034

      The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.

      23 April 2024

      READ
      Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

      The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

      18 April 2024

      READ
      Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

      The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

      17 April 2024

      READ
      Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

      The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

      12 April 2024

      READ